Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Proprietary Cost Model Development & Maintenance

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract focuses on the maintenance and enhancement of proprietary cost-estimating tools and methodologies currently utilized by the incumbent contractor for National Geospatial-Intelligence Agency (NGA) programs. The work involves ongoing development and refinement of these specialized cost models to support accurate and efficient budget forecasting and program management. The contract is categorized under NAICS code 541714, which pertains to research and development in the physical, engineering, and life sciences. The contract is issued by the Department of Defense and will be performed in Springfield, with a ZIP code of 22150. Although specific set-aside details or organization types are not provided, the contract serves a critical role in supporting defense-related geospatial intelligence initiatives through advanced cost modeling services. This effort ensures the continued reliability and improvement of financial estimation tools that underpin major projects within NGA programs.

General Info

Maintenance and enhancement of NGA proprietary cost-estimating tools for defense geospatial intelligence programs.

Agency

Department Of Defense → Attn Ms S84 OcsView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Springfield, VA, 22150, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Attn Ms S84 Ocs
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Defense → Attn Ms S84 Ocs
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Maintain and enhance proprietary cost-estimating tools and methodologies used by the incumbent contractor for NGA programs.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Combines Synopsis Solicitation- iPSC DifferentiatiThe National Institutes of Health, through its Office of the Director and Office of Acquisitions, is seeking to award a firm fixed-price contract on a non-competitive basis to Oxford StemTech Ltd of Oxford, UK, for scientific support services related to the quality control of induced pluripotent stem cells and the generation and characterization of organoids using a subset of these cell lines. This acquisition is conducted under streamlined commercial item procedures outlined in FAR Subpart 12.6 and is not expected to exceed the simplified acquisition threshold, with authority derived from FAR 12.603, 41 U.S.C. 1901, and FAR 6.302-3(a)(2)(ii). The solicitation, identified by number 75N98026Q00878, serves as both the notice of intent and the sole solicitation document, eliminating the need for a separate formal request. The contract is classified under NAICS code 541714 and is being procured without competition due to the unique technical capabilities required and the specialized nature of the services. The response deadline for proposals is July 31, 2026, at 6:00 p.m. Eastern Time, with the posting date listed as July 27, 2026. All submissions must be directed to the designated point of contact, John R. Johnson, reachable via email at johnsonjr@mail.nih.gov, with the contract performance to be carried out in Bethesda, Maryland. The contract will be executed under the authority of the Department of Health and Human Services, and no set-asides or small business preferences are applicable. The offering entity, Oxford StemTech Ltd, has been identified as the only qualified source capable of delivering the required services, justifying the non-competitive approach under the specified regulatory exceptions.
National Institutes Of Health Olao

POSTED

about 14 hours ago

DEADLINE

in 4 days
View Details
NAICS: 541714
New
Federal
Humanized Antibody Library Screening and Transferrin Receptor DevelopmentThe contract involves the customized screening of a humanized antibody library to develop a functional transferrin receptor, encompassing molecular design, in vitro selection, and optimization of binding affinity and specificity. The work requires advanced techniques in antibody engineering to identify and refine candidates capable of high-affinity, selective interaction with the transferrin receptor, with the goal of producing a therapeutically viable candidate. The scope includes iterative cycles of library screening, functional characterization, and structural optimization to enhance target binding while minimizing off-target interactions, ensuring the final product meets stringent performance benchmarks. This subcontract is issued under the NAICS code 541714 for research and development in the biological sciences and is associated with the National Institutes of Health through the Department of Health and Human Services. The place of performance is in Bethesda, Maryland, with a deadline for proposals set for July 31, 2026. The contract is expected to support biomedical innovation targeting receptor-mediated delivery systems and requires expertise in molecular biology, high-throughput screening, and protein engineering. No specific set-aside provisions are indicated, and the work is open to qualified subcontractors capable of delivering scalable, data-driven antibody development solutions within the defined timeline.
National Institutes Of Health Olao

POSTED

4 days ago

DEADLINE

in 3 days
View Details
NAICS: 541714
New
Federal
Develop and Validate Transferrin ReceptorThe National Institutes of Health, under the Department of Health and Human Services, has issued a presolicitation notice for the development and validation of a transferrin receptor, identified by solicitation number 75N98026Q00866. This opportunity is open for responses until July 31, 2026, and was posted on July 24, 2026, with no set-aside provisions applied, making it open to all eligible entities. The work will be performed in Bethesda, Maryland, and falls under the NAICS code 541714, which corresponds to research and development in the physical, engineering, and life sciences. The primary point of contact for inquiries is Towanda Daniels, reachable via email at danielt@mail.nih.gov. Interested parties are directed to the official SAM.gov workspace link for further details and submission guidelines. The contract aims to support advanced scientific research focused on the transferrin receptor, likely to advance biomedical applications or therapeutic technologies. All proposals must adhere to the requirements outlined in the notice of intent, and submissions should be prepared with consideration for the technical scope, timeline, and performance standards expected by the NIH Office of Laboratory Animal Welfare. The contract is structured to enable innovation in molecular biology or drug delivery systems involving receptor targeting, with performance expected within the confines of federal research protocols and compliance standards.
National Institutes Of Health Olao

POSTED

4 days ago

DEADLINE

in 3 days
View Details
NAICS: 541714
New
Federal
Notice of Intent to Award a Sole Source Contract – Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreakThe Food and Drug Administration is planning to award a sole source firm-fixed price purchase order to The University of Liverpool under simplified acquisition procedures for the sequencing of Bundibugyo virus disease during the 2026 outbreak, relying on FAR Part 6.103-1 which permits non-competitive procurement when only one responsible source exists. This action falls under the NAICS code 541714 for Research and Development in Biotechnology and is not open for competitive bidding, as the FDA has determined that The University of Liverpool is the only entity with the necessary expertise and capacity to meet the technical requirements for this highly specific viral sequencing effort. The contract is intended to support bioanalytical method development and sample analysis by providing critical reagents and reference standards for quantifying CYP enzyme substrates and metabolites in hepatocyte experiments during the outbreak response. Responses to this notice must be submitted by Ryan Alexander at ryan.alexander@fda.hhs.gov no later than 5:00 pm on July 29, 2026, and must include a detailed capability statement for any other organization seeking consideration, though the government retains full discretion to determine whether a response justifies competitive solicitation. The procurement is not a request for competitive quotes, and no set-aside is being applied. The contract will be administered from the FDA’s office in Rockville, Maryland, with performance primarily occurring in Liverpool, England, and the solicitation number is OC-2026-135667, issued on July 24, 2026.
Food And Drug Administration

POSTED

4 days ago

DEADLINE

in 2 days
View Details
NAICS: 541714
New
Federal
Procurement of lateral flow (LFA) strips for the rapid HIV nucleic acid diagnostic testThe Centers for Disease Control and Prevention is soliciting bids for the procurement of 4,000 lateral flow strips intended for use in a rapid HIV nucleic acid diagnostic test under a firm-fixed-price contract, issued as a Request for Quote in accordance with FAR Subpart 12 for commercial items. The solicitation number is 75D30126Q79099, with a performance period of August 1, 2026, to December 31, 2026, and an option to extend services for up to six additional months. Proposals must be submitted electronically to Eugene Gutierrez at zvm0@cdc.gov no later than 3:00 P.M. Eastern Standard Time on Friday, July 24, 2026, with no telephonic or paper submissions accepted. The place of performance is the CDC facility at 1600 Clifton Road, Building 17, Atlanta, GA 30329-4018. Offerors must be registered in the System for Award Management at the time of submission and are required to comply with all applicable FAR clauses, including 52.212-1 and 52.212-4, along with deviations such as those addressing trafficking in persons, contractor employee whistleblower rights, sustainable products and services, Buy American Act alternatives for Israeli and Korean end products, and prohibitions on unauthorized information sharing. Technical evaluation is the predominant factor in award, emphasizing experience with biomedical devices, FDA approval processes, and prior work with lateral flow technology, with price considered secondary. The contractor must deliver 200 prototype strips and 4,000 final units meeting stringent performance standards: ≤0.5% false positive rate and ≤1% false negative rate using CDC’s LAMP reaction, and must ensure full compatibility with CDC’s mass production protocols. All deliverables must conform to Section 508 accessibility requirements, including WCAG 2.0 Level AA, and vendors must provide a Voluntary Product Accessibility Template or HHS conformance checklist. The contract imposes strict security and confidentiality obligations, including mandatory non-disclosure agreements for all employees accessing sensitive information, identification protocols to distinguish contractor personnel from government staff, and prohibitions against retaining or disseminating federal records or Privacy Act data. Subcontractors must be bound by the same requirements, and all payments must be processed via the Treasury’s Invoice Processing Platform using an ACH Vendor Enrollment
CDC Office Of Acquisition Services

POSTED

4 days ago

DEADLINE

in 1 day
View Details
NAICS: 541714
New
Federal
Battlefield Pain Management – AnalgesicThis solicitation, identified as HT942726RE009 and titled Battlefield Pain Management – Analgesic, is issued under the Defense Health Agency’s prototype Other Transaction Authority (pOTA) authority pursuant to 10 U.S.C. § 4022 to acquire a single-use analgesic product for battlefield use, with the goal of achieving FDA approval for acute moderate to severe pain. The product must be administered rapidly and easily, possess a small physical profile for individual carry, and remain stable without refrigeration across extreme temperature conditions ranging from -25°C to 45°C, with a required shelf life of 2–3 years at controlled room temperature. It must comply with USP <659> packaging standards and meet stringent quality system requirements under 21 CFR Part 820, including labeling control and documentation of chemical composition. The product must be classified as DEA Schedule II or higher and may utilize a device-based delivery method such as a nasal spray or autoinjector, with physiological constraints limiting blood pressure and heart rate decreases to no more than 20% and preserving blood clotting capacity with minimal airway impact. The project spans an estimated eight years divided into three objectives—Chemistry, Manufacturing, and Controls (CMC) and stability studies over three years, non-clinical enabling studies over two years, and clinical trials and human factors testing over three years, contingent on successful completion of prior phases. Proposals must be submitted in three distinct volumes—Technical, Management, and Administrative and Cost—and adhere to strict formatting requirements including searchable PDF format, page limits for specified sections, and inclusion of a Microsoft Project file for the schedule. The submission window was extended from July 30, 2026, to August 14, 2026, with questions due by July 10, 2026, and must be sent via email to designated points of contact. Proposals must demonstrate at least one pass/fail gate condition: participation of a nontraditional defense contractor or nonprofit research institute to a significant extent; all significant participants being small businesses or nontraditional contractors; or cost-sharing from non-federal sources accounting for at least one-third of the total project cost. Evaluation focuses on technical approach, management strategy, and cost structure, with award determined by the most advantageous proposal. The agreement is not subject to the FAR or DFARS, except for referenced clauses such as DFARS 252.232-
Defense Health Agency

POSTED

5 days ago

DEADLINE

in 18 days
View Details

More opportunities from Department Of Defense → Attn Ms S84 Ocs

Same awarding agency